ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "biologic response modifiers"

  • Abstract Number: 0818 • ACR Convergence 2021

    Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry

    Nancy Guo1, Xiuying Li2, Mohammad Movahedi3, Angela Cesta4 and Claire Bombardier5, 1Kingston General Hospital, Kingston, ON, Canada, 2OBRI at University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
  • Abstract Number: 1217 • ACR Convergence 2021

    Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada

    Mohammad Movahedi1, Denis Choquette2, Louis Coupal2, Angela Cesta3, Xiuying Li3, Edward Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 4Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
  • Abstract Number: 1219 • ACR Convergence 2021

    Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

    Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
  • Abstract Number: 1732 • ACR Convergence 2021

    Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2 and Ruru Guo3, 1Saint Agnes Healthcare, Baltimore, MD, 2Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai, China (People's Republic)

    Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
  • Abstract Number: 0719 • ACR Convergence 2020

    Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study

    Edoardo Marrani1, Hendrik Rusche2, Francesco Terzani3, Elisa Peroni4, Feliciana Real-Fernandez5, Olivier Monasson4, Roberta Ponti6, Gabriele Simonini7, Anna Maria Papini3 and Paolo Rovero5, 1University of Florence, Firenze, Italy, 2[email protected] and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, 3PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, 4[email protected] and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, 5PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, 6Pediatric Department, University of Udine, udine, Italy, 7Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy

    Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
  • Abstract Number: 0833 • ACR Convergence 2020

    Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics

    Andrea De Diego Sola1, César Antonio Egües Dubuc2, Nerea Alcorta Lorenzo1, Jesús Alejandro Valero Jaimes2, Olga Maíz Alonso3, Luis Maria Lopez Dominguez1, Esther Uriarte Isacelaya4, Jorge Cancio Fanlo5, María Asunción Aranguren Redondo6, María Belén Irastorza Larburu7 and Joaquín María Belzunegui Otano3, 1Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Pais Vasco, Spain, 2Hospital Universitario Donostia, San Sebastián, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Universitario Donostia, San Sebastian, Spain, 5Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 6Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 7Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastián, Spain

    Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) ("treat-to-treat" strategy).  Once sustained remission is achieved,…
  • Abstract Number: 0901 • ACR Convergence 2020

    Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence

    Robert Moots1, Andy Cross2, Helen Wright2, Steven Edwards2, Nicola Goodson3, Jenny Hawkes3, Ayren Mediana1 and Helen Frankland1, 1Liverpool University Hospitals, Liverpool, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3University of Liverpool, Liverpool

    Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA). …
  • Abstract Number: 1014 • ACR Convergence 2020

    Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years

    John Hanly1 and Lynn Lethbridge2, 1Dalhousie University, Halifax, NS, Canada, 2Dalhousie University, Halifax, Canada

    Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
  • Abstract Number: 1240 • ACR Convergence 2020

    An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis

    Muhammad Shipa1, Su-Ann Yeoh1, Dev Mukerjee2 and Michael Ehrenstein1, 1University College London, LONDON, United Kingdom, 2North Middlesex University hospital NHS Trust, London, United Kingdom

    Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
  • Abstract Number: 1376 • ACR Convergence 2020

    Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis

    Valeria Rios Rodriguez1, Mikhail Protopopov1, Fabian Proft1, Judith Rademacher1, Burkhard Muche1, Anne-Katrin Weber1, Susanne Lüders1, Hildrun Haibel1, Maryna Verba1, Joachim Sieper1 and Denis Poddubnyy2, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Data on the impact of body weight and body mass index (BMI) on the response to biological disease-modifying anti-rheumatic drugs (bDMARDs) in axial spondyloarthritis…
  • Abstract Number: 1898 • ACR Convergence 2020

    Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis

    Loïc Choquette Sauvageau1, Denis Choquette2, Louis Bessette3, Isabelle Ferdinand1, Boulos Haraoui4, Frédéric Massicotte1, Jean-Pierre Pelletier2, Jean-Pierre Raynauld2, Marie-Anaïs Rémillard1, Diane Sauvageau1, Édith Villeneuve1 and Louis Coupal1, 1Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 2Institut de Rhumatologie de Montréal, Montreal, Canada, 3Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, 4Rheumatology Institute of Montréal, Montreal, Canada

    Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
  • Abstract Number: 2005 • ACR Convergence 2020

    Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis

    Felice Rivellese1, Frances Humby2, Giovanni Giorli2, Alessandra Nerviani1, Rebecca Hands2, Liliane Fossati-Jimack2, Georgina Thorborn2, Myles Lewis1 and Costantino Pitzalis2, 1Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 2Queen Mary University of London, London, United Kingdom

    Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
  • Abstract Number: 2032 • ACR Convergence 2020

    Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis

    Valeria Rios Rodriguez1, Mikhail Protopopov1, Fabian Proft1, Judith Rademacher1, Burkhard Muche1, Anne-Katrin Weber1, Susanne Lüders1, Hildrun Haibel1, Maryna Verba1, Joachim Sieper1 and Denis Poddubnyy2, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
  • Abstract Number: 0227 • ACR Convergence 2020

    Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors

    Lucía Vega-Álvarez1, Itziar Calvo-Zorrilla1, Oihane Ibarguengoitia-Barrena1, Juan M. Blanco-Madrigal1, David Montero-Seisdedos2, Carmen L. Garcia-Gomez1, Maria Esther Ruiz-Lucea1, Ana R. Inchaurbe-Pellejero1, Ignacio Torre-Salaberri1, Clara E. Perez-Velasquez1, Olaia Fernandez-Berrizbeitia1, Eduardo Cuende-Quintana3, Iñigo R. Gorostiza-Hormaetxe4, María Luz García-Vivar1 and Eva Galindez-Agirregoikoa1, 1Basurto University Hospital, BILBAO, Spain, 2Basurto University Hospital, Bilbao, Pais Vasco, Spain, 3Basurto University Hospital, Madrid, Spain, 4Basurto University Hospital, Bilbao

    Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
  • Abstract Number: 0333 • ACR Convergence 2020

    Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis

    Denis Choquette1, Loïc Choquette Sauvageau2, Louis Bessette3, Isabelle Ferdinand2, Boulos Haraoui4, Frédéric Massicotte2, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard2, Diane Sauvageau2, Édith Villeneuve2 and Louis Coupal2, 1Institut de Rhumatologie de Montréal, Montreal, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Laval University, Quebec, Canada, 4Rheumatology Institute of Montréal, Montreal, Canada

    Background/Purpose: The treatment of psoriatic arthritis has evolved with the addition of agents targeting a different cytokine, Il-17 introduced in 2016. It has proven to…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies